Schedule 13G ownership disclosure
Kymera Therapeutics Inc
Common Stock · CUSIP: 501575104
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Wellington Management Group LLP
Shares: 5,307,326.00 · Class: 8.2%
- Wellington Group Holdings LLP
Shares: 5,307,326.00 · Class: 8.2%
- Wellington Investment Advisors Holdings LLP
Shares: 5,307,326.00 · Class: 8.2%
- Wellington Management Company LLP
Shares: 5,307,326.00 · Class: 8.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902219-25-000097
- Form type
- SCHEDULE 13G/A
- Filer
- Kymera Therapeutics, Inc.
- CIK
- CIK 1815442
- Filed
- Feb 10, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership